2 active not recruiting, 2 completed, 2 recruiting, 2 terminated. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Active not recruiting 2, Completed 2, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Recurrent Mycosis Fungoides: new trials by email Literature Review of Recurrent Mycosis Fungoides trials Research Report on Recurrent Mycosis Fungoides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides | Phase 1 | Withdrawn | City of Hope Medical Center | 2019-03-01 | 2019-04-30 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-25 | 2026-10-29 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Durvalumab, Laboratory Biomarker Analysis, Lenalidomide - Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 78 | 2017-03-08 | 2026-07-31 |
| Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2016-09-13 | 2026-10-26 |
Mycosis Fungoides (9) · Lymphoma, T-Cell (6) · Lymphoma, T-Cell, Cutaneous (6) · Lymphoma, Large-Cell, Anaplastic (4) · Immunoblastic Lymphadenopathy (3) · Sezary Syndrome (3) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Breast Neoplasms (1) · Enteropathy-Associated T-Cell Lymphoma (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma, Non-Hodgkin (8) · Lymphadenopathy (3) · Lymphoma, T-Cell (3) · Lymphoma, T-Cell, Cutaneous (3) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Breast Diseases (1)
Disulfides (3) · Immunoglobulin G (3) · Magnetic Resonance Spectroscopy (3) · pembrolizumab (3) · Biopsy (2) · Cyclophosphamide (2) · Depsipeptides (2) · Lactones (2) · Lenalidomide (2) · Nivolumab (2) · Specimen Handling (2) · romidepsin (2) · 10-propargyl-10-deazaaminopterin (1) · AFM13 (1) · Brentuximab Vedotin (1)
City of Hope Medical Center (3) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2)
United States (9) · Canada (1)
Alex F Herrera (1) · Christiane Querfeld, MD (1) · Grzegorz S. Nowakowski, M.D. (1) · Jasmine Zain, MD (1) · Joselle Cook, M.B.B.S. (1) · Julio C Chavez (1) · Michael S Khodadoust (1) · Nora Bennani, M.D. (1) · Swaminathan P Iyer, MD (1) · Yago L Nieto (1)
PMID 32632956, PMID 35175355, PMID 36826995, PMID 36898933, PMID 39951620, PMID 40186077
P50CA186781 (1), R01CA229510 (1), R01CA262613 (1), UM1CA186644 (1), UM1CA186717 (1)